Absence of Glucagon and Insulin Action Reveals a Role for the GLP-1 Receptor in Endogenous Glucose Production
The DOI matches its Crossref record; 46 of the 47 references it cites were found in a registry or an index.
Abstract
The absence of insulin results in oscillating hyperglycemia and ketoacidosis in type 1 diabetes. Remarkably, mice genetically deficient in the glucagon receptor (Gcgr) are refractory to the pathophysiological symptoms of insulin deficiency, and therefore, studies interrogating this unique model may uncover metabolic regulatory mechanisms that are independent of insulin. A significant feature of Gcgr-null mice is the high circulating concentrations of GLP-1. Hence, the objective of this report was to investigate potential noninsulinotropic roles of GLP-1 in mice where GCGR signaling is inactivated. For these studies, pancreatic β-cells were chemically destroyed by streptozotocin (STZ) in Gcgr−/−:Glp-1r−/− mice and in Glp-1r−/− animals that were subsequently treated with a high-affinity GCGR antagonist antibody that recapitulates the physiological state of Gcgr ablation. Loss of GLP-1 action substantially worsened nonfasting glucose concentrations and glucose tolerance in mice deficient in, and undergoing pharmacological inhibition of, the GCGR. Further, lack of the Glp-1r in STZ-treated Gcgr−/− mice elevated rates of endogenous glucose production, likely accounting for the differences in glucose homeostasis. These results support the emerging hypothesis that non–β-cell actions of GLP-1 analogs may improve metabolic control in patients with insulinopenic diabetes.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 reduces hepatic glucose production, partly by inhibiting the expression and activity of key gluconeogenic enzymes.189–191”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [190]
Citations
Cites
Pharmacology, physiology, and mechanisms of incretin hormone action.
Campbell, J. E., & Drucker, D. J. (2013) · Cell Metabolism · doi:10.1016/j.cmet.2013.04.008 · Cited by 1,500 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialDiabetes mellitus : a fundamental and clinical text
LeRoith, D., Taylor, S. I., & Olefsky, J. M. (2004) · Cited by 699
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680 · cited 4×
“Use of the Gcgr, Glp-1r, and Gcgr:Glp-1r genetic models here builds on previous work in Gcgr mice showing that administration of the GLP-1R peptide antagonist, exendin-4(9-39), worsens glucose tolerance in these animals (19).”
BackgroundMethodResultInfluentialGlucagonocentric restructuring of diabetes: A pathophysiologic and therapeutic makeover
Unger, R. H., & Cherrington, A. D. (2012) · Journal of Clinical Investigation · doi:10.1172/jci60016 · Cited by 670 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialThe essential role of glucagon in the pathogenesis of diabetes mellitus
Unger, R., & Orci, L. (1975) · The Lancet · doi:10.1016/s0140-6736(75)92375-2 · Cited by 599 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialGlucagon-like Peptide-1 Receptor Signaling Modulates β Cell Apoptosis
Li, Y., Hansotia, T., Yusta, B., Ris, F., Halban, P. A., & Drucker, D. J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m209423200 · Cited by 589
Gelling, R. W., Du, X. Q., Dichmann, D. S., Rømer, J., Huang, H., Cui, L., Obici, S., Tang, B., Holst, J. J., Fledelius, C., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0237106100 · Cited by 563
Richards, P., Parker, H. E., Adriaenssens, A. E., Hodgson, J. M., Cork, S. C., Trapp, S., Gribble, F. M., & Reimann, F. (2014) · Diabetes · doi:10.2337/db13-1440 · Cited by 472 · cited 5×
“These results are similar to those showing acute blockade of the GLP-1R using exendin-4(9-39) worsens glucose tolerance in STZ-treated Gcgr-null mice (19).”
BackgroundMethodResultInfluentialEleazu, C. O., Eleazu, K. C., Chukwuma, S., & Essien, U. N. (2013) · Journal of Diabetes & Metabolic Disorders · doi:10.1186/2251-6581-12-60 · Cited by 459 · cited 5×
“Studies have demonstrated that Gcgr mice administered the diabetogenic chemical agent streptozotocin (STZ), a cytotoxic glucose analog that induces necrotic destruction of pancreatic b-cells (15), are resistant to STZ-induced hyperglycemia (14).”
BackgroundMethodResultInfluentialGerich, J. E., Lorenzi, M., Bier, D. M., Schneider, V., Tsalikian, E., Karam, J. H., & Forsham, P. H. (1975) · New England Journal of Medicine · doi:10.1056/nejm197505082921901 · Cited by 354
Cited by
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868
“Further, glucagon receptor KO mice also have compensatory increases in a-cell GLP-1, and GLP-1 receptor (GLP-1R) signaling has been reported to contribute to the preserved glucose responses after streptozotocin administration [166,167].”
BackgroundGlucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
Coskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Self-citationIslet α cells and glucagon--critical regulators of energy homeostasis
Campbell, J. E., & Drucker, D. J. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.51 · Cited by 266
The glucoregulatory actions of leptin
D'souza, A. M., Neumann, U. H., Glavas, M. M., & Kieffer, T. J. (2017) · Molecular Metabolism · doi:10.1016/j.molmet.2017.04.011 · Cited by 216
Autocrine selection of a GLP-1R G-protein biased agonist with potent antidiabetic effects
Zhang, H., Sturchler, E., Zhu, J., Nieto, A., Cistrone, P. A., Xie, J., He, L., Yea, K., Jones, T., Turn, R., et al. (2015) · Nature Communications · doi:10.1038/ncomms9918 · Cited by 137
The Biology of Glucagon and the Consequences of Hyperglucagonemia
Wewer Albrechtsen, N. J., Kuhre, R. E., Pedersen, J., Knop, F. K., & Holst, J. J. (2016) · Biomarkers in Medicine · doi:10.2217/bmm-2016-0090 · Cited by 129
Glucagon – Early breakthroughs and recent discoveries
Åhrén, B. (2015) · Peptides · doi:10.1016/j.peptides.2015.03.011 · Cited by 134
Repositioning Glucagon Action in the Physiology and Pharmacology of Diabetes
Finan, B., Capozzi, M. E., & Campbell, J. E. (2020) · Diabetes · doi:10.2337/dbi19-0004 · Cited by 118
“However, a number of studies have demonstrated that the glucose lowering in response to a GRA or following genetic deletion of the glucagon receptor (GCGR) are severely diminished in the absence of GLP-1R signaling (44, 46-48).”
BackgroundGalsgaard, K. D., Winther-Sørensen, M., Ørskov, C., Kissow, H., Poulsen, S. S., Vilstrup, H., Prehn, C., Adamski, J., Jepsen, S. L., Hartmann, B., et al. (2018) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00198.2017 · Cited by 115
“The larger amount of 382 active GLP-1 in the pancreas may result in increased concentrations of circulating GLP-1 (14) in 383 Gcgr -/mice, and this has been suggested as an underlying reason for the improved glucose 384 tolerance of these mice (11, 22).”
BackgroundMechanisms controlling hormone secretion in human gut and its relevance to metabolism
Martin, A. M., Sun, E. W., & Keating, D. J. (2020) · Journal of Endocrinology · doi:10.1530/joe-19-0399 · Cited by 109
The past, present, and future physiology and pharmacology of glucagon
Capozzi, M. E., D’Alessio, D. A., & Campbell, J. E. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.10.001 · Cited by 109
Zhang, Y., Parajuli, K. R., Fava, G. E., Gupta, R., Xu, W., Nguyen, L. U., Zakaria, A. F., Fonseca, V. A., Wang, H., Mauvais-Jarvis, F., et al. (2019) · Diabetes · doi:10.2337/db18-0317 · Cited by 104
“For Glp1r-LoxPmice, we used the novel hGLP-1R mouse model (19,20).”
MethodSelf-citationInsulin and Glucagon: Partners for Life
Holst, J. J., Holland, W., Gromada, J., Lee, Y., Unger, R. H., Yan, H., Sloop, K. W., Kieffer, T. J., Damond, N., & Herrera, P. L. (2017) · Endocrinology · doi:10.1210/en.2016-1748 · Cited by 90
“Similarly, Steenberg et al. (29) also generated acute glucagon cell–depleted mice by using diphtheria toxin, but the massive reduction in pancreatic glucagon cells and glucagon content did not result in improvement of the severe type 1 diabetic phenotype after large doses of STZ.”
BackgroundInfluentialSelf-citationSmits, M. M., Tonneijck, L., Muskiet, M. H. A., Kramer, M. H. H., Cahen, D. L., & van Raalte, D. H. (2016) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12593 · Cited by 74
Blockade of glucagon signaling prevents or reverses diabetes onset only if residual β-cells persist
Damond, N., Thorel, F., Moyers, J. S., Charron, M. J., Vuguin, P. M., Powers, A. C., & Herrera, P. L. (2016) · eLife · doi:10.7554/elife.13828 · Cited by 74
Hepatogenous diabetes: Is it time to separate it from type 2 diabetes?
Orsi, E., Grancini, V., Menini, S., Aghemo, A., & Pugliese, G. (2016) · Liver International · doi:10.1111/liv.13337 · Cited by 84
“In fact, in addition to inhibiting glucagon secretion, incretin hormones directly suppress endogenous glucose production through an isletindependent mechanism [70].”
Bifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Vagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
The Limited Role of Glucagon for Ketogenesis During Fasting or in Response to SGLT2 Inhibition
Capozzi, M. E., Coch, R. W., Koech, J., Astapova, I. I., Wait, J. B., Encisco, S. E., Douros, J. D., EL, K. M., Finan, B., Sloop, K. W., et al. (2020) · Diabetes · doi:10.2337/db19-1216 · Cited by 65
“For studies using Ab-4, 10 mg/kg i.p. was administered 24 h prior to fasting plasma collection.”
MethodInfluentialSelf-citationRegulation of amino acid metabolism and α‐cell proliferation by glucagon
Hayashi, Y., & Seino, Y. (2018) · Journal of Diabetes Investigation · doi:10.1111/jdi.12797 · Cited by 59
Kaur, M., & Misra, S. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03646-0 · Cited by 51
“It was demonstrated that the medication functionally activates GCGR in vivo and increases blood sugar levels when evaluated without GIPR and GLP-1R agonism by employing a GCGR antibody antagonist prior to treatment [32].”
Wei, T., Cui, X., Jiang, Y., Wang, K., Wang, D., Li, F., Lin, X., Gu, L., Yang, K., Yang, J., et al. (2023) · Diabetes · doi:10.2337/db22-0784 · Cited by 50
“Hyperglucagonemia and an elevated GLP-1 level are common when the glucagon–GCGR signaling pathway is blocked (25,26), making it complicated to clarify which hormone activates GLP-1R and whether the activatedGLP-1R is responsible forb-cell regeneration.”
BackgroundWang, M.-Y., Dean, E. D., Quittner-Strom, E. B., Zhu, Y., Chowdhury, K. H., Zhang, Z., Zhao, S., Li, N., Ye, R., Lee, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2022142118 · Cited by 55
“1 d in rodents, and it lacks any binding affinity for glucagon-like peptide-1 receptor (13).”
BackgroundSelf-citationInhibiting or antagonizing glucagon: making progress in diabetes care
Lefèbvre, P. J., Paquot, N., & Scheen, A. J. (2015) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12480 · Cited by 44
Cabrera, O., FICORILLI, J. V., Shaw, J., Echeverri, F., Schwede, F., Chepurny, O. G., Leech, C. A., & Holz, G. G. (2021) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2021.101484 · Cited by 45
GPR142 prompts glucagon-like Peptide-1 release from islets to improve β cell function
Lin, H. V., Wang, J., Wang, J., Wei-ji, L., Wang, X., Alston, J. T., Thomas, M. K., Briere, D. A., Syed, S. K., & Efanov, A. M. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.02.008 · Cited by 35
“Glp1r knockout [15] and Gipr knockout mice on C57BL/6 background were maintained at Taconic (Hudson, NY).”
MethodEvidence for the existence and potential roles of intra-islet glucagon-like peptide-1
Campbell, S. A., Johnson, J., & Light, P. E. (2021) · Islets · doi:10.1080/19382014.2021.1889941 · Cited by 42
Pettus, J., D’Alessio, D. A., Frías, J. P., Vajda, E. G., Pipkin, J. D., Rosenstock, J., Williamson, G., Zangmeister, M. A., Zhi, L., & Marschke, K. B. (2019) · Diabetes Care · doi:10.2337/dc19-1328 · Cited by 35
Zheng, X., Cao, C., He, Y., Wang, X., Wu, J., & Hu, H. (2021) · Lipids in Health and Disease · doi:10.1186/s12944-021-01485-x · Cited by 34
Neumann, U. H., Ho, J. S. S., Mojibian, M., Covey, S. D., Charron, M. J., & Kieffer, T. J. (2016) · Molecular Metabolism · doi:10.1016/j.molmet.2016.05.014 · Cited by 29
“Glucagon plays a role not only in the fasting state but also in the fed state, which is evident as Gcgr gene deletion can normalize fed blood glucose levels and glucose tolerance [3,4,6].”
BackgroundJiang, L., Wang, S.-Q., Ding, B., Zhu, J., Jing, T., Ye, L., Lee, K., Wu, J., & Ma, J. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0765-0 · Cited by 29
Iida, A., Seino, Y., Fukami, A., Maekawa, R., Yabe, D., Shimizu, S., Kinoshita, K., Takagi, Y., Izumoto, T., Ogata, H., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-3935-2 · Cited by 27
“Both models are deficient in GLP-1 action and exhibit hyperglycaemia on STZ treatment, underscoring the critical importance of GLP-1 on glycaemic control under STZ-induced beta cell ablation [30–32].”
Rivero‐Gutiérrez, B., Haller, A. M., Holland, J., Yates, E., Khrisna, R., Habegger, K. M., DiMarchi, R. D., D’Alessio, D. A., & Pérez–Tilve, D. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.07.012 · Cited by 24
Schneider, R., Kraljević, M., Peterli, R., Rohm, T. V., Klasen, J. M., Cavelti‐Weder, C., & Delko, T. (2020) · Obesity Surgery · doi:10.1007/s11695-020-04750-7 · Cited by 18
“1 Mechanisms by which GLP-1 analogues may have beneficial effects after metabolic surgery: GIT [16, 17], brain [14, 18, 19], cardiovascular system [20, 21], kidneys [22], skeletal muscle [23], adipose tissue [24, 25], liver [26, 27], and endocrine pancreas [15, 28, 29].”
BackgroundThe Role of Glucagon in Glycemic Variability in Type 1 Diabetes: A Narrative Review
Guo, K., Tian, Q., Yang, L., & Zhou, Z. (2021) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s343514 · Cited by 20
Takagi, Y., Kinoshita, K., Ozaki, N., Seino, Y., Murata, Y., Oshida, Y., & Hayashi, Y. (2015) · PLoS ONE · doi:10.1371/journal.pone.0138322 · Cited by 13
“Jun et al recently demonstrated that loss of GLP-1 action aggravates glucose tolerance in mice deficient in glucagon receptor [32].”
BackgroundHepato-Incretin Function of GLP-1: Novel Concept and Target in Type 1 Diabetes
Ahrén, B. (2015) · Diabetes · doi:10.2337/db14-1671 · Cited by 13
“(10) proceeded further, however, by examining endogenous glucose production.”
BackgroundResultInfluentialIslet hormones at the intersection of glucose and amino acid metabolism
White, P. J., Albrechtsen, N. J. W., & Campbell, J. E. (2025) · Nature Reviews Endocrinology · doi:10.1038/s41574-025-01100-4 · Cited by 18
“Interestingly, in Glp1r -knockout models both genetic and pharmacological interference with glucagon activity fail to reduce glycaemia 102,103 .”
Ceron, E. L., Reddy, S. D., Kattamuri, L. P. V., Muvva, D. M., Chozet, L. E., & Bright, T. M. (2025) · Journal of Brown Hospital Medicine · doi:10.56305/001c.132255 · Cited by 20
Pancreatic islet α cell function and proliferation requires the arginine transporter SLC7A2Preprint
Spears, E., Stanley, J. E., Shou, M., Yin, L., Li, X., Dai, C., Bradley, A. M., Sellick, K., Poffenberger, G., Coate, K. C., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.08.10.552656 · Cited by 11
Self-citationα cells use both PC1/3 and PC2 to process proglucagon peptides and control insulin secretion
Cui, C., Leander, D. C., Gray, S. M., EL, K. M., Chen, A. Y., Grimsrud, P. A., Becker, J. O., Taylor, A. J., Zhang, G., Sloop, K. W., et al. (2025) · Science Advances · doi:10.1126/sciadv.ady8048 · Cited by 15
“This controversy was heightened by observations that STZ-induced β cell damage ( 31 ) or reduction in glucagon signaling ( 45 , 46 ) increased islet PC1/3 expression and GLP-1 content.”
Self-citationSubramanian, V., Bagger, J. I., Harihar, V., Holst, J. J., Knop, F. K., & Villsbøll, T. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00278.2023 · Cited by 12
Novel Insulin Receptor-Signaling Platform
Haxho, F. (2014) · International Journal of Diabetes and Clinical Research · doi:10.23937/2377-3634/1410005 · Cited by 10
Kamemoto, K., Tataka, Y., Hiratsu, A., Nagayama, C., Hamada, Y., Kurata, K., Chiyoda, M., Ito, M., & Miyashita, M. (2024) · Scientific Reports · doi:10.1038/s41598-024-58103-w · Cited by 12
“Inhibition of gluconeogenesis in the liver is independent of GLP-1 function in the pancreatic islets 26 , and GLP-1 has attracted attention for its role in improving glucose tolerance.”
BackgroundThe interaction of ASIC1a and ERS mediates nerve cell apoptosis induced by insulin deficiency
Pan, X., Zhu, Y., Wu, X. G., Liu, L., Ying, R., Wang, L., Du, N., Zhang, J., Jin, J., Meng, X., et al. (2020) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2020.173816 · Cited by 7
Physiology and pharmacology of glucagon-like peptide-1 receptor
Куркин, Д. В., Bakulin, D. A., Morkovin, E. I., Petrov, V. I., Strygin, A. V., Koryanova, K. N., Gorbunova, Y. V., Kolosov, Y. A., Ivanova, O. V., Pavlova, E. V., et al. (2024) · Pharmacy & Pharmacology · doi:10.19163/2307-9266-2023-11-4-347-380 · Cited by 13
Chou, I.-W., Cheng, R. Y.-H., Chen, Y., Hsieh, P. C. H., & King, K. (2017) · Scientific Reports · doi:10.1038/s41598-017-12290-x · Cited by 7
Evidence for time dependent variation of glucagon secretion in mice
Malmgren, S., & Åhrén, B. (2016) · Peptides · doi:10.1016/j.peptides.2016.01.008 · Cited by 3
Liraglutide improved glycaemic instability in a patient with diabetes with insulin antibodies
Kato, T., Iizuka, K., Niwa, H., & Takeda, J. (2016) · BMJ Case Reports · doi:10.1136/bcr-2016-216028 · Cited by 3
Almohammad, A. A., Aldossari, S. K., Sukumbaji, Z. A., Faden, R. A., Almutairi, M. A., Al-Harbi, N. H., Al-Saaib, M. Y., Almarshedy, B., Alharabi, E., Alhazri, W. A., et al. (2025) · Cureus · doi:10.7759/cureus.95792 · Cited by 9
Pancreatic islet α cell function and proliferation require the arginine transporter SLC7A2
Spears, E., Stanley, J. E., Shou, M., Yin, L., Li, X., Dai, C., BRADLEY, A., Sellick, K., Poffenberger, G., Coate, K. C., et al. (2026) · Journal of Clinical Investigation · doi:10.1172/jci173913 · Cited by 17
“To interrupt glucagon signaling, mice were treated weekly with 10 mg/kg of a humanized monoclonal antibody targeting the glucagon receptor (GCGR mAb “Ab-4”) intra-peritoneally once a week for 2 weeks (59).”
Self-citationModern technologies in management of diabetes
Iqbal, A., Qadir, M. I., & Asif, M. (2017) · Journal of College of Medical Sciences-Nepal · doi:10.3126/jcmsn.v13i2.16921 · Cited by 2
Advances in basic research on glucagon and alpha cells
Hayashi, Y. (2024) · Diabetology International · doi:10.1007/s13340-024-00696-8 · Cited by 3
“Whereas mice deficient in glucagon receptors display resistance to streptozotocin-induced diabetes [8], mice deficient in receptors for both glucagon and glucagon-like peptide-1 (GLP-1) are sensitive [11].”
Estes, S. K., Shiota, C., O’Brien, T. P., Printz, R. L., & Shiota, M. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00192.2023 · Cited by 1
Savoldelli, R. D. (2016) · Digital Library of Theses and Dissertations (Universidade de São Paulo) · doi:10.11606/t.5.2016.tde-07122016-152749 · Cited by 1
The metabolic effects of leptin therapy and glucagon suppression therapy in mouse models of diabetes
Neumann, U. H. (2017) · cIRcle (University of British Columbia) · doi:10.14288/1.0348695
“Glucagon not only plays a role in the fasting state but also in the fed state, which is evident as Gcgr gene deletion can normalize fed blood glucose levels and glucose tolerance [74, 75, 342].”
BackgroundInfluentialNaftalin, R. J. (2021) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.739653703.793583651
Arble, D. M., Hutch, C. R., Hafner, H., Stelmak, D., Leix, K., Sorrell, J. E., Pressler, J. W., Gregg, B. E., & Sandoval, D. A. (2023) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00152.2022 · Cited by 1
Madhoun, A. S. A., Malik, M. Z., Albeloushi, S., ABUKHALAF, N. A., Miranda, L., Jacob, S., Nizam, R., John, S., GEORGE, P., Channanath, A. M., et al. (2026) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-026-06275-1
Metadata
- Authors
- Jun, L. S., Millican, R. L., Hawkins, E. D., Konkol, D. L., Showalter, A. D., Christe, M. E., Michael, M. D., & Sloop, K. W.
- Affiliations
- Eli Lilly (United States) (US)
- Corresponding author
- Sloop, Kyle W.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2014-10-06
- Volume
- 64
- Issue
- 3
- Pages
- 819-827
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- OpenAlex
- W2106971468
- Cited by
- 60
- References
- 47
- Citations by year
- 2026: 2 · 2025: 4 · 2024: 6 · 2023: 4 · 2022: 2 · 2021: 6 · 2020: 3 · 2019: 4 · 2018: 5 · 2017: 7 · 2016: 8 · 2015: 8 · 2014: 1
- FWCI
- 6.43
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- GLP-1 receptor, glucagon receptor, endogenous glucose production, glucose homeostasis, insulin deficiency, type 1 diabetes, glucagon, glucose tolerance, hyperglycemia, ketoacidosis
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Animals, Glucagon, Glucose, Immunohistochemistry, Insulin, Streptozocin, Receptors, Glucagon, Mice, Knockout, Mice, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.